Take­da takes a cau­tious step in­to neu­ro­log­i­cal gene ther­a­py, ink­ing pre­clin­i­cal deal with Stride­Bio

Sad­dled with debt and keen to di­vest non-core busi­ness amid the on­go­ing in­te­gra­tion of Shire, Take­da has nev­er­the­less dished out a small sum to beef …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.